Evidence map›Paper›PMID 33762742›Full record

ArticleCell death and differentiation2021

MECOM permits pancreatic acinar cell dedifferentiation avoiding cell death under stress conditions.

Elyne Backx, Elke Wauters, Jonathan Baldan, Mathias Van Bulck, Ellis Michiels, Yves Heremans, Diedert Luc De Paep, Mineo Kurokawa, Susumu Goyama, Luc Bouwens and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Cell death and differentiation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Pancreatic Organoids for Regenerative Medicine and Cancer Research.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Elyne BackxLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België.
Elke WautersCell Differentiation Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.
Jonathan BaldanCell Differentiation Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.
Mathias Van BulckLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België.
Ellis MichielsLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België.
Yves HeremansLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België.
Diedert Luc De PaepBeta Cell Bank, Universitair Ziekenhuis Brussel, Brussels, Belgium and Diabetes Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.ORCID http://orcid.org/0000-0001-8969-6531
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Susumu GoyamaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Luc BouwensCell Differentiation Laboratory, Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, 1090, Belgium.
Patrick JacqueminLaboratory of Liver and Pancreatic Differentiation, De Duve Institute, Université Catholique de Louvain, Hippokrateslaan 75, Brussels, 1200, Belgium.
Isabelle HoubrackenLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België.
Ilse RoomanLaboratory of Medical and Molecular Oncology, Oncology Research Center, Vrije Universiteit Brussel, Laarbeeklaan 103, Jette, 1090, België. irooman@vub.be.
Vrije Universiteit Brussel · BEThe University of Tokyo · JPde Duve Institute · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maintenance of the pancreatic acinar cell phenotype suppresses tumor formation. Hence, repetitive acute or chronic pancreatitis, stress conditions in which the acinar cells dedifferentiate, predispose for cancer formation in the pancreas. Dedifferentiated acinar cells acquire a large panel of duct cell-specific markers. However, it remains unclear to what extent dedifferentiated acini differ from native duct cells and which genes are uniquely regulating acinar cell dedifferentiation. Moreover, most studies have been performed on mice since the availability of human cells is scarce. Here, we applied a non-genetic lineage tracing method of human pancreatic exocrine acinar and duct cells that allowed cell-type-specific gene expression profiling by RNA sequencing. Subsequent to this discovery analysis, one transcription factor that was unique for dedifferentiated acinar cells was functionally characterized. RNA sequencing analysis showed that human dedifferentiated acinar cells expressed genes in "Pathways of cancer" with a prominence of MECOM (EVI-1), a transcription factor that was not expressed by duct cells. During mouse embryonic development, pre-acinar cells also transiently expressed MECOM and in the adult mouse pancreas, MECOM was re-expressed when mice were subjected to acute and chronic pancreatitis, conditions in which acinar cells dedifferentiate. In human cells and in mice, MECOM expression correlated with and was directly regulated by SOX9. Mouse acinar cells that, by genetic manipulation, lose the ability to upregulate MECOM showed impaired cell adhesion, more prominent acinar cell death, and suppressed acinar cell dedifferentiation by limited ERK signaling. In conclusion, we transcriptionally profiled the two major human pancreatic exocrine cell types, acinar and duct cells, during experimental stress conditions. We provide insights that in dedifferentiated acinar cells, cancer pathways are upregulated in which MECOM is a critical regulator that suppresses acinar cell death by permitting cellular dedifferentiation.

Indexed as

Acinar CellsAnimalsCell DeathCell DedifferentiationDisease Models, AnimalHumansMDS1 and EVI1 Complex Locus ProteinMiceOncogenesSignal TransductionMDS1 and EVI1 Complex Locus ProteinMecom protein, mouse

Identifiers

PMID33762742
PMCPMC8408219
OpenAlexW3139105845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.